🇺🇸 3,4-diaminopyridine in United States

29 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Condition Aggravated — 3 reports (10.34%)
  2. Cough — 3 reports (10.34%)
  3. Cyanosis — 3 reports (10.34%)
  4. Depressed Level Of Consciousness — 3 reports (10.34%)
  5. Drooling — 3 reports (10.34%)
  6. Dyspnoea — 3 reports (10.34%)
  7. Hypotonia — 3 reports (10.34%)
  8. Increased Bronchial Secretion — 3 reports (10.34%)
  9. Respiratory Depression — 3 reports (10.34%)
  10. Asthenia — 2 reports (6.9%)

Source database →

Other Neurology approved in United States

Frequently asked questions

Is 3,4-diaminopyridine approved in United States?

3,4-diaminopyridine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for 3,4-diaminopyridine in United States?

Oregon Health and Science University is the originator. The local marketing authorisation holder may differ — check the official source linked above.